Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
2022-11-22 04:59
Telix Acquires Optimal Tracers
2022-11-14 06:36
Telix to Present at Jefferies London Healthcare Conference 2022
2022-11-11 20:00
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
2022-11-07 06:48
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022
2022-10-27 10:23
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
2022-10-27 06:44
Telix Reports Third Quarter 2022 Financial Results
2022-10-20 06:09
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
2022-10-18 06:43
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
2022-10-17 13:00
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
2022-10-17 07:25
Health Canada Approves Illuccix® for Prostate Cancer Imaging
2022-10-14 08:21
First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
2022-09-30 02:30
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
2022-09-28 06:50
First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
2022-09-28 05:00
First Patient Enrolled in ProstACT TARGET Study
2022-09-27 05:00
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
2022-09-21 07:51
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment
2022-08-24 05:56
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
2022-08-08 07:55
Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
2022-08-02 06:54
BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging
2022-07-27 20:30
1
2
3
4
5
6
6